Alphageneron Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $2M

Overview

Alphageneron Pharmaceuticals is a clinical-stage biotech pioneering a targeted NK cell therapy platform centered on the cancer-specific biomarker mHsp70. Its pipeline includes both autologous and allogeneic NK cell therapies, as well as a CAR-NK candidate derived from induced pluripotent stem cells (iPSCs). Led by a founder with a history of biotech ventures and a board featuring seasoned industry and academic experts, the company is positioned in the competitive but high-potential cell therapy space for solid tumors.

Oncology

Technology Platform

Targeted natural killer (NK) cell therapy platform focused on the membrane Hsp70 (mHsp70) cancer biomarker, encompassing autologous, allogeneic, CAR-engineered, and iPSC-derived NK cell modalities.

Funding History

1

Total raised:$2M

Seed$2MUndisclosedJun 15, 2021

Opportunities

The significant unmet need in solid tumor oncology and the growing validation of NK cells as a safer, potentially more effective modality than T-cells for solid tumors presents a major opportunity.

Success with its 'off-the-shelf' allogeneic or iPSC-derived platforms could position Alphageneron for partnerships or as an attractive acquisition target for larger pharma companies seeking cell therapy assets.

Risk Factors

Key risks include the unproven clinical efficacy of the mHsp70 target in advanced trials, intense competition in the NK cell therapy space from better-funded rivals, and the substantial financial and manufacturing complexities associated with developing scalable allogeneic and iPSC-derived cell therapies.

Competitive Landscape

Alphageneron operates in the highly competitive NK cell therapy arena, competing with numerous biotechs (e.g., Nkarta, Fate Therapeutics, Century Therapeutics) and large pharma partners developing allogeneic and iPSC-derived NK and CAR-NK therapies. Differentiation relies on the uniqueness of the mHsp70 target and the efficacy of its specific engineering approaches.

More companies in Cell & Gene Therapy →More companies in United States →